M-M-R II Rx
Generic Name and Formulations:
Measles, mumps and rubella viruses live, attenuated; for SC inj; contains neomycin, human albumin; preservative-free.
Merck & Co., Inc.
- Limb-Sparing Surgery Plus Radiotherapy May Improve Survival Outcomes in Soft-Tissue Sarcoma
- Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma
- Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes
- Esophageal and Esophagogastric Junction Cancer Treatment Regimens
- Colon Cancer Treatment Regimens
- Leukemia Treatment Regimens: Acute Lymphoblastic Leukemia (ALL)
Indications for M-M-R II:
Measles, mumps and rubella immunization. A 2nd dose of measles vaccine is recommended.
Adults and Children:
<12 months: usually not recommended. Each dose is 0.5mL. Give by SC inj into upper outer arm. First dose at 12–15 months of age, second dose at 4–6yrs of age (ACIP recommendations).
Egg, gelatin, or neomycin hypersensitivity. Active respiratory or other febrile infection. Active untreated tuberculosis. Immunosuppression. Blood dyscrasias. Bone marrow or lymphatic malignancy. Pregnancy (Cat.C) during and for 3 months after vaccination.
Have epinephrine inj available. History of febrile convulsions or cerebral injury. Defer vaccination for at least 3 months after blood or plasma transfusions or immune serum globulin, and for at least 1 month before or after other live virus vaccines (except oral polio). Nursing mothers: not recommended.
Immunosuppressants (see Contraindications). May interfere with tuberculin test.
Fever, rash, malaise, sore throat, headache, local reactions, arthritic symptoms, parotitis, orchitis, thrombocytopenia, purpura; encephalitis (rare).
Single dose vial—1, 10 (w. diluent); Multi-dose vial—1 (w. diluent)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- IL-23 Drives Castration-Resistant Prostate Cancer
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer
- Lenalidomide-Based Maintenance Therapy May Be the Most Effective in Myeloma
- Approximately Two-Thirds of Patients With Stage IV Bladder Cancer Remain Untreated
- Aspirin and Colorectal Cancer